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2MurG is an essential bacterial glycosyltransferase that catalyses the GlcNAc-transformation of 
lipid I to lipid II during peptidoglycan biosynthesis. Park’s nucleotide has been a convenient 
biochemical tool to study the function of MraY and MurG, however, no fluorescent probe has been 
developed to differentiate individual processes in the biotransformation of Park’s nucleotide to 
lipid II via lipid I. Herein, we report a robust assay of MurG using either the membrane fraction 
of a M. smegmatis strain or a thermostable MraY and MurG of Hydrogenivirga sp. as enzyme 
sources, along with Park’s nucleotide or Park’s nucleotide-N-C6-dansylthiourea and UDP-GlcN-
C6-FITC as acceptor and donor substrates. Identification of both the MraY and MurG products can 
be performed simultaneously by HPLC in dual UV mode. Conveniently, the generated lipid II 
fluorescent analogue can also be quantitated via UV-Vis spectrometry without separation of the 
unreacted lipid I derivative. The microplate-based assay reported here is amenable to high-
throughput MurG screening. A preliminary screening of a collection of small molecules has 
demonstrated the robustness of the assays, and resulted in rediscovery of ristocetin A as a strong 
antimycobacterial MurG and MraY inhibitor.
KEYWORDS: MurG translocase II, Lipid II, MraY translocase I, Lipid 
I, Park’s nucleotide, Fluorescence-based assay, ristocetin
Glycosyltransferases (GTases) play an important role in the 
carbohydrate metabolisms in all living organisms.1,2 Many bacterial 
GTases are involved in cell wall biosynthesis transferring a 
carbohydrate unit from a nucleotide donor to a lipid-containing 
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3acceptor. Of this group, the membrane-associated and essential 
GTase, MurG (UDP-N-acetylglucosamine:N-acetylmuramyl-
(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine 
transferase) catalyzes the rate-limiting step of lipid II (GlcNAc-
MurNAc-(pentapeptide)-pyrophosphoryl prenol) synthesis by 
transferring GlcNAc from UDP-GlcNAc to lipid I (MurNAc-
(pentapeptide)-pyrophosphoryl prenol). Lipid I synthesis is 
catalyzed by the transmembrane protein MraY/MurX (phospho-MurNAc-
(pentapeptide) translocase) which transfers a MurNAc-pentapide 
from Park’s nucleotide to a phosphoprenol acceptor (Figure 1).3-5 
Lipid II is then transferred across the cytoplasmic membrane to 
the outer leaflet where penicillin binding proteins 
(transpeptidases and transglycosylases) polymerize and cross-link 
lipid II to form peptidoglycan. We previously reported both 
chemoenzymatic and total chemical synthesis of Park’s nucleotide 
and its assay probes that allowed for the development of a 
convenient assay method for MraY/MurX.6-16 We have now extended our 
functional studies and inhibitor designs into MurG. Previously, 
the effect of inhibitor molecules on the biosynthesis of 
peptidoglycan has been monitored via radiolabeled precursors 
(e.g., UDP-GlcNAc, UDP-MurNAc-(pentapeptide), and prenyl-P) with 
cell-free particulate fractions.17 For MurG, enzyme inhibition can 
be monitored by the incorporation of a radiolabeled UDP-GlcNAc 
into lipid II using Park’s nucleotide. However, this requires 
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4subsequent separation of radiolabeled product from excess isotope-
labeled substrates for quantitation. Moreover, the coupling assays 
with Park’s nucleotide and UDP-GlcNAc cause false-positive errors 
if molecules have MraY inhibitory activity. A number of assays 
were developed subsequent to this. A biotinylated lipid I analog 
was introduced and an avidin-derivatized resin was applied to 
remove excess [14C]UDP-GlcNAc (Men et al. 1998 and Branstorm et al. 
1999).18-20 The Walker group developed a high-throughput screening 
(HTS) method to identify MurG UDP-GlcNAc antagonist utilizing 
fluorescence polarization (Helm et al. 2003).21 Conceptually unique 
UDP-GlcNAc probes having 2-(1H-indol-3-yl)acetamide were developed for MurG assay via 
Förster resonance energy transfer method (Li et al. 2004).22 The Wong group 
developed a MurG assay coupled with pyruvate kinase and lactic 
dehydrogenase, where MurG inhibitory activity is indirectly 
measured by the decrease of fluorescence of NADH (ex =340 nm, em 
= 460 nm) (Liu et al. 2003).23 There are still a few MurG assays 
that can monitor inhibition of the lipid II transformation without 
relying on radioisotope(s). Lipid I or its analogs developed for 
MurG assays require total chemical synthesis.19,24-28 On the other 
hand, Park’s nucleotide can readily be obtained via enzymatic 
reactions from UDP-GlcNAc using MurA-F or from UDP-MurNAc using 
MurC-F chemo-enzymatically.6 Unlike lipid I, Park’s nucleotide is 
a water soluble molecule, and amenable to a medium scale synthesis 
and convenient  purification methods. Therefore, the ideal method 
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5to study MurG function systematically would 1) avoid 
radioisotopes, 2) start with Park’s nucleotide, and 3) allow for 
the differentiation of MraY and MurG inhibitory activity. We have 
developed MurG assays using intact Park’s nucleotide (10) or Park’s 
nucleotide-N-C6-dansylthiourea fluorescent probe (1e), UDP-GlcN-
C6-FITC (8), and exogenous C55-prenyl phosphate. Here we describe 
1) the substrate tolerance of MurG, 2) novel MurG assay methods 
that do not require separation of the unreacted lipid I 
intermediate, and 3) characterization of MurG of Hydrogenivirga 
sp. (HyMurG) and Mycobacterium smegmatis (MsmegMurG) as convenient 
sources for HTS.
Figure 1.  Biosynthesis of lipid I and lipid II.
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6Structures of Park’s nucleotide and lipid I probes recognized by 
MraY/MurX and MurG. We have extensively studied the probing of 
Park’s nucleotide that can be recognized by translocase I (MraY 
and MurX).8 As summarized in Table 1, the lysine nitrogen (N-
position) of Park’s nucleotide was modified with the sulfonyl 
chloride (-SO2Cl) or isothiocyanate (-N=C=S) of dansyl and 
fluorescein derivatives and all probes (1a-g) were effective in 
the formation of the corresponding lipid I-N-derivatives (50-60% 
yield via HPLC) using the crude membrane (P-60) prepared from a 
wild-type M. smegmatis strain (ATCC607). In our studies of lipid-
acceptor, MurX and MraY showed tolerance in the length and E/Z-
geometry of the -double bond, but the -double bond is required 
to be in the Z-configuration; P-60-catalyzed reaction of 1a-g with 
neryl phosphate (C10-P) and (2Z,6E)-farnesyl phosphate (C15-P) 
furnished the corresponding lipid I-N-derivatives in 60-80% yield 
(entries 3, 4, 8, 9, 13, 14, 18, and 19 in Table 1). On the other 
hand, (2Z)-phytyl phosphate did not provide the corresponding 
lipid I derivatives (entries 5, 10, 15, 20, 25, 30, and 36). It is 
worthwhile mentioning that C10- and C15-lipid I-N-derivatives are 
dissolved in the reaction buffer solutions, and these combinations 
have been applied to convenient MraY/MurX assays.8,9 On the other 
hand, none of the Park’s nucleotide probes (1a-d) modified with 
commercial reagents at the lysine N-position were effective in 
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7the formation of lipid II analogues with P-60 in the presence of 
UDP-GlcNAc (entries 1-20). With a C6-linker (6-aminohexanol) 
bridging to Park’s nucleotide, two types of dansyl fluorophores 
could be substrates for both MraY and MurG (entries 21,22, 26, and 
27). In contrast, the lipid I-C6-FITC derivatives (e.g., 2g-C55) 
were not recognized by 
MurG (entries 32 and 33 
in Table 1). 
Table 1. Park's 
nucleotide and lipid I 
fluorescent probes 
effective in MurX- and 
MurG-catalysed 
reactions.
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8Unmodified lipid I and lipid II are difficult products to 
differentiate by reversed-phase chromatography. To establish an 
assay, we synthesized C55-lipid I-C6-dansyl (2e-C55) according to 
the synthetic scheme established previously with minor 
modifications (see, Scheme 1).7,27 We then converted the synthetic 
lipid I analogue, 2e-C55 to C55-lipid II-C6-dansyl (3e-C55) with P-
60 of M. smegmatis. Purified Park’s nucleotide, lipid I, and lipid 
II derivatives (1e, 2e-C55, and 3e-C55) were used to establish HPLC-
based assays for monitoring both MurX/MraY and MurG enzyme 
activities.8,9,27 We commenced HPLC studies with 2f-C55 and 3f-C55, 
establishing the best separation in retention times. The peak 
separation of 1 min was achieved via a gradient elution with 0.05 
M NH4HCO3 and MeOH (15:85 to 0:100 over 30 min.). As shown in Figure 
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92B, separation of the peaks of lipid I and lipid II derivatives 
was better with 2e-C55 and 3e-C55; the difference between the 
retention time was over 3 min. Due to this observed chromatographic 
advantage, the Park’s nucleotide probe 1e was chosen for MurG assay 
development. MurG exhibited lower tolerance in the structure of 
the fluorescent probe at the lysine N-C6-linker and the donor 
substrate, prenyl phosphate, than those of MurX/MraY. The lipid I-
C6-dansyl derivatives of neryl (C10) and (2Z,6E)-farnesyl 
phosphates (C15) were not converted to the corresponding lipid II 
analogues by using P-60 of M. smegmatis (entries 23, 24, and 25 in 
Table 1). We have continued exploring prenyl group mimetics that 
can be the substrates for both MurX/MraY and MurG, however, so 
far, natural forms of C55-P and C50-P are the only prenyl phosphates 
that fulfilled the biotransformation from 1e to 2e-C55 and 3e-C55. 
In the transformation of Figure 2A, over 50% of the lipid I 
derivative, 2e-C55 was generated within 1 h that was, in turn, 
consumed to <10% after 2 h, furnishing the lipid II derivative, 
3e-C55 in 70% (42% overall yield based on consumption of 1e) (Figure 
2C).
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10
Figure 2. A: Biotransformations of lipid I and lipid II 
derivatives, 2e-C55 and 3e-C55, from Park's nucleotide N-C6-
dansyl, 1e. B: HPLC chromatography of 1e, 2e-C55, and 3e-C55. C: 
Kinetics of transformation from 1e to 2e-C55, and 3e-C55 in A.
Convenient source of MraY and MurG. We reported that MurX- and 
MraY-containing membrane fractions (P-60) obtained from wild-type 
M. tuberculosis, M. smegmatis, and E. coli strains could convert 
the Park’s nucleotide probes (1b and 1f in Table 1) to the 
corresponding lipid I analogues in 5-70% yields with 3 equivalents 
of C55- or C50-phosphate.8 This variation in yield conversion is 
dependent on the expression level of MurX/MraY. Mycobacterium spp. 
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11
express MraY-type phosphotransferase much higher than Gram-
negative and -positive bacteria.29 As demonstrated in Figure 3A, 
P-60 of a wild-type M. smegmatis strain could convert Park's 
nucleotide N-C6-dansylthiourea (1e) to C55-lipid I-N-C6-
dansylthiourea (2e-C55) in 60% yield and to C55-lipid II-N-C6-
dansyl, 3e-C55 in 42% yield. To perform screening against MurG 
using crude membrane fractions, 1e should be converted to 2e-C55 
in >90% yield in situ. We have been unable to successfully 
overexpress Mycobacterial MurX in E. coli. As an alternative, it 
has been demonstrated that recombinant proteins from M. 
thermoresistibile (Mtherm) are useful surrogates for production of 
problematic Mycobacterial proteins.30 We successfully expressed 
MthermMurX in E. coli and were able to purify it to a single 
homogenous species. As reported before,9 we have also routinely 
expressed and purified MraY of Hydrogenivirga spp. to study the 
catalytic mechanism and obtain insight into the binding mode of 
MraY/MurX inhibitors. Time-course experiments of prenylation of 1e 
with MraY/MurX from different sources of bacteria revealed that 
HyMraY (2.5 M) yielded 2e-C55 in 95-100% yield within 1 h (Figure 
3B). At the same concentration, MthermMurX furnished 2e-C55 in 70% 
yield, requiring a concentration of 5.0 M to attain a similar 
level of conversion to that observed with HyMraY. Taking advantage 
of high-yielding 2e-C55 in a low concentration, we decided to apply 
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the purified HyMraY to convert 1e to 2e-C55, and 2e-C55 generated 
in situ was used in the following MurG reactions (protocol A). 
Alternatively, the MurX activity can be terminated completely by 
addition of an MraY/MurX inhibitor, tunicamycin (50 M). The MurG 
function of P-60 remains active after the addition of tunicamycin 
(protocol B). The latter protocol is particularly useful to study 
membrane fractions containing MurG where purification proves 
difficult (Figure 3C). Using MurG of a pathogen of research 
interest is ideal to discover selective antibacterial MurG 
inhibitors. Gamma-irradiated M. tuberculosis (NR-14819) obtained 
from BEI Resources has been a useful P-60 source for MtbMurG 
studies. However, it has proven unreliable as we often note a 
failure of the transformation from 1e to 3e-C55 due to an inactive 
P-60 membrane fraction from the obatined Mtb cells (Figure 2A). We 
turned to an M. smegmatis (ATCC607) strain that can serve as a 
surrogate of M. tuberculosis (H37Rv) to predict susceptibility of 
TB drugs under a slow growth condition.31 The IC50 levels of MraY 
inhibitors (e.g., tunicamycin, capuramycin, and muraymycins) 
obtained with MtbMurX were well-correlated with those with 
MsmegMurX. Importantly, M. smegmatis (ATCC607) can readily be 
cultured without an enrichment (growth rate: 48-72h at 37 oC to 
reach the OD value of 0.9). Thus, sufficient P-60 membrane fraction 
can be readily prepared from this M. smegmatis strain. In this 
study, it was determined that P-60 of M. smegmatis (ATCC607) is 
Page 12 of 64
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13
also a convenient surrogate for MtbMurG. We could expressed HyMurG 
in E. coli and successfully purified as its active form. Figure 3D 
summarises 3e-C55 yield-time curves for the transformation (2e-
C553e-C55) using MurG enzymes from different sources. Under the 
conditions developed for MraY/MurG-catalyzed reactions (Figure 
3A), 2e-C55 was converted to 3e-C55 in 80% and 100% yield with 2.5 
M and 5.0 M concentration of HyMurG, respectively. P-60 of M. 
smegmatis required 10 L (1 mg wet weight/L) to convert 2e-C55 to 
3e-C55 in 30-40% yield in a 50 L scale. Conversion from 2e-C55 to 
3e-C55 was dependent on P-60 concentration; MurG reaction with 30 
L of P-60 of M. smegmatis provided 3e-C55 in 70% yield. P-60 
Membrane fractions prepared from wild-type S. aureus and E. coli 
were also examined. The same reaction with 30 L of P-60 of E. 
coli provided 3e-C55 in less than 10% conversion of 3e-C55, and P-
60 of S. aureus yielded 3e-C55 in 25%. These results suggested that 
P-60 of M. smegmatis is a convenient and reliable source to convert 
Park’s nucleotide to lipid II through lipid I and to identify 
antimycobacterial MurG inhibitors. Purified HyMurG is a robust 
enzyme, which is stable through repeated freezing and thawing 
cycles. Thus, we were interested in applying HyMurG as a convenient 
MurG source for discovering antibacterial MurG agents via HTS.
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Figure 3.  Establishment of a MurG assay using Park's nucleotide-N-
C6-dansylthiourea, 1e.
Synthesis of C55-lipid I-N-C6-dansyl, 2e-C55, for kinetic studies. 
We have previously reported chemical syntheses of Park’s 
nucleotide, lipid I, and lipid II.6,7,27 Synthesis of C55-lipid I-
N-C6-dansylthioure (2e-C55) was adapted to the synthetic schemes 
developed for lipid I with minor modifications.7,9,27 Synthesis of 
2e-C55 is summarized in Scheme 1. The common N-acetylmuramic acid 
(MurNAc) intermediate 4 was subjected to debenzylation of the 
anomeric position, and the generated free-alcohol was 
phosphorylated to form 5 in 85% overall yield with exclusive 
selectivity to the -diasteromer by two step procedures of 
0
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phosphite formation with dibenzyl N,N-diisopropylphosphoramidite 
and 5-(ethylthio)-1H-tetrazole followed by oxidation with aq. 
tBuO2H.9 Deprotection of the 2-(phenylsulfonyl)ethanol group of 5 
was achieved by the treatment with DBU to furnish the free-
carboxylic acid, which was coupled with the tetrapeptide, 
Scheme 1.  Chemical synthesis of C55-lipid I-N-C6-dansylthiourea, 
2e-C55.
HCl•H--D-Glu(OMe)-L-Lys(COCF3)-D-Ala-D-Ala-OMe, under EDCI, 
Glyceroacetonide-Oxima (GOx),32,33 NaHCO3 in DMF-H2O, furnishing the 
-phosphoryl MurNAc-pentapeptide 6 in 90% overall yield. 
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Hydrogenolitic debenzylations of 6 followed by the treatment with 
excess Et3N resulted in the corresponding monotriethylammonium 
phosphate, which was subjected to a carbonyldiimidazole (CDI)-
promoted diphosphate-formation reaction with an ammonium salt of 
undecaprenyl phosphate (C55-P-NH4). The fully protected lipid I 
moeity was coverted to lipid I (7) by saponification with LiOH in 
THF-H2O. The crude lipid I was purified via reverse-phase HPLC 
(0.05 M NH4HCO3 : MeOH = 15 : 85 to 0 : 100 over 30 min, retention 
time : 25 min.) to furnish pure lipid I in 60% overall yield from 
6. Lipid I could be stored in a 4 : 1 mixture of DMSO and 0.05M 
NaHCO3 at -20 oC for over 8 months without decomposition. An aliquot 
of lipid I was converted to lipid I-N-C6-dansylthiourea (2e-C55) 
in 80% overall yield in 3 steps from 7 including carbamate 
formation at the N-position with SuO-C(O)O-(CH2)6-NHCOCF3, 
deprotection of the CF3CO group, and thiourea formation with 4-
(dansylamino)phenyl isothiocyanate. The structure of synthetic 2e-
C55 was confirmed by 1H-NMR, LC-MS, and comparison of retention 
time with 2e-C55 synthesized from 1e using P-60 of M. smegmatis 
(Figure 2A).
Table 2.  Apparent Km values for C55-lipid I-N-C6-dansylthiourea 
(2e-C55) and UDP-GlcNAc at the different concentartions of the 
counterpart (UDP-GlcNAc or 2e-C55)a.
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Kinetic studies. Kinetic studies provide insight into the 
catalytic mecahnism and help to optimize enymatic assay 
conditions. The kinetic parameters of MurG of M. smegmatis were 
investigated by varying concentrations of the substrates (2e-C55 
and UDP-GlcNAc). The apparent Km for 2e-C55 was determined to be 40 
± 5.0 M at 375 M of UDP-GlcNAc, and the apparent Km for UDP-
GlcNAc 35 ± 8.1 M at 300 M of 2e-C55. Many bacterial glycosyl 
transferases are believed to involve a ternary complex reaction 
mechanism.34,35 We further elaborated MurG kinetic studies to 
confirm its reaction mechanism whether MurG follows a ternary 
complex reaction mechanism using the new probe. The correlation 
C55-lipid I-N-C6-dansylthiourea (2e-C55)
concentration (M)
C55-lipid I-N-C6-dansylthiourea
(2e-C55)
C55-lipid II-N-C6-dansylthiourea
(3e-C55)
1h
P-60 (M. smegmatis)
UDP
Km of UDP-GlcNAc
(M)
37.5 36  10b
75.0 37  3.0
150 36  5.0
225
300 35  8.1b
36  2.2
UDP-GlcNAc
concentration (M)
Km of C55-lipid I-N-C6-dansylthiourea (2e-C55)
(M)
46.9 13  3.0b
62.5 25  3.0
93.8 36  5.0
187.5
375.0 40  5.0b
39  3.0
UDP-GlcNAc
a All reactions were performed in the presence of MgCl2 (50 M)
b Higher and lower concentrations were repeated three times.
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between the concentrations of 2e-C55 or UDP-GlcNAc (x axis) and the 
reaction velocity (V) of 3e-C55 (y axis) at several fixed 
concentrations of UDP-GlcNAc or 2e-C55 was summarized in supporting 
information (SI) and the Km values for the enzymatic substrates 
are shown in Table 2. The Km values of UDP-GlcNAc were similar over 
the range of concentrations of 2e-C55. The Km values of 2e-C55 were 
also similar in a range between 93.8-375.0 M of UDP-GlcNAc. The 
observations that different Km values were provided at lower 
concentrations of UDP-GlcNAc (below 62.5 M); they may suggest 
that UDP-GlcNAc concentration affects MurG activity. These data indicate that 1) MurG 
catalyzes lipid II formation via a ternary complex mechanism in which lipid I and UDP-GlcNAc 
bind together to the enzyme, and 2) the lipid I analogue, 2e-C55, is an appropraite 
assay probe. Because detection limitation of the dansyl substrates (2e-C55 and 3e-C55) via 
UV-detector, kinetic studies were limited to higher than 12.5 M of 2e-C55. Analogously, kinetic 
studies with HyMurG were performed. The Km value for 2e-C55 was 40 ± 7.0 M at the 
concentration of 375 M of UDP-GlcNAc; the Km (HyMurG) value was near equal to that obtained 
with MsmegMurG (Km: 40 ± 5.0 M). The Vmax for the synthesis of lipid II analogue, 3e-C55, by 
P-60 of M. smegmatis was determined to be 0.98 M/min and 2.0 M/min for HyMurG. These 
kinetic parameters are not conclusive indexes to compare the catalytic effectiveness, however, 
these data support a faster-yielding 2e-C55 with HyMurG compared with the same reaction with 
P-60 of M. smegmatis (Figure 3C). Under the same reaction condition (buffer, detergent, pH, and 
temperature), the kcat values of HyMurG and HyMraY for 2e-C55 and 1e were determine to be 0.18 
s-1 and 0.38 s-1, respectively, indicating that the turnover rate of MraY, which converts Park’s 
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nucleotide to lipid I, is faster than that of MurG, which converts lipid I to lipid II. The Km and kcat 
values of EcoliMurG were reported to be 37-44 M and 0.27-0.32 s-1 for the lipid I biotinylated 
analogue, respectively.19 Thus, these kinetic parameters indicated that affinity and catalytic 
turnover efficiency of MurG are similar among E. coli, Hydrogenivirga sp. and 
Mycobacterium spp. 
Application of UDP-Glucosamine-C6-FITC (UDP-GlcN-C6-FITC) to MurG 
assay. Previously, the intact UDP-GlcNAc and its radiolabeled 
substrates were the only nucleosides that have been applied in 
transformations with glycosyltransferases that utilize UDP-GlcNAc 
as the donor substrate. We have developed UDP-GlcN-C6-FITC probe 
(8) for assaying polyprenyl phosphate-GlcNAc-1-phosphate 
transferase (WecA),36 which catalyzes the conversion from UDP-
GlcNAc to decaprenyl-P-P-GlcNAc. It was demonstrated, for the 
first time, that a UDP-GlcNAc-fluorescent probe can be a substrate 
for a glycosyltransferase. To facilitate the screening against 
MurG using coupled assays with Park’s nucleotide, tolerability of 
MurG against 8 was examined using P-60 of M. smegmatis and purified 
HyMurG. Gratifyingly, under the same condition developed in Figure 
2, GlcN-C6-FITC addition to C55-lipid I-N-C6-dansyl (2e-C55) with 8 
was catalyzed by P-60 of M. smegmatis and HyMurG to form C55-lipid 
II-N-C6-dansyl-FITC (9-C55) in 60-70% and 100% yield, respectively 
(Figure 4A). C55-lipid II-N-C6-dansyl-FITC (9-C55) can be detected 
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by either 350 nm (for the dansyl group) or 485 nm (for the FITC 
group) or both wave lengths if a dual-wavelength UV detector is 
equipped with HPLC system (Figure 4B). The lipid I and II 
possessing different UV-visible absorbance have a significant 
advantage in undoubtedly distinguishing the enzymatic substrate 
and product in HPLC; regardless of chromatographic separation, 
only 9-C55 can be detected at 485 nm and both 2e-C55 and 9-C55 
detected at 350 nm. Thus, MurG assays with 1e (or 2e-C55) and 8 
will not provide false-positive or -negative results. The Km value 
for UDP-GlcN-C6-FITC probe (8) was 54 M at the concentrations of 
75 M of C55-lipid I-N-C6-dansylthiourea (2e-C55); this was similar 
to the Km values obtained with lipid I (7) (Km: 49 M). The Vmax 
values for C55-lipid II-N-C6-dansyl-FITC (9-C55) transformation by 
P-60 of M. smegmatis and HyMurG were determined to be 0.56 and 
0.67 M/min, respectively. In competition reactions in P-60 (M. 
smegmatis)-catalyzed lipid II synthesis with UDP-GlcN-C6-FITC 
probe (8) at 375 M in the presence of UDP-GlcNAc (by varying 
concentration), 100%-disappearance of 9-C55 required >200 M of 
UDP-GlcNAc (IC50 8.40 M, Figure 5). These kinetic parameters (Km 
54 M for 8 and Km 44 M for UDP-GlcNAc, and similar Vmax value of 
0.5-0.6 M/min) imply that 8 is an appropriate UDP-GlcNAc mimetic 
for MurG-catalyzed lipid II analogue formations. It is worthwhile 
mentioning that MraY/MurX followed by MurG-catalyzed lipid II 
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synthesis from either Park’s nucleotide (10) or Park's nucleotide-
N-C6-dansylthiourea (1e) illustrated in Figure 4A is not a 
reversible process and polymerizations of C55-lipid II-FITC (11-
C55) and C55-lipid II-N-C6-dansyl-FITC (9-C55) were not observed 
with P-60 of M. smegmatis.37 Thus, product yields for the lipid I 
and lipid II analogues are very high without addition of inhibitors 
of penicillin binding proteins.38
Figure 4. A: Biotransformation of lipid II derivatives, 9-C55 
from Park's nucleotide-N-C6-dansylthiourea (1e). B: HPLC 
chromatography of 1e, 2e-C55, 9-C55, Park's nucleotide (10), and 
C55-lipid II-FITC (11-C55).
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Figure 5. Competitive reaction of UDP-GlcN-C6-FITC (8) and UDP-
GlcNAc in the biotransformation of 9-C55.
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MeOH : 0.05 M NH4HCO3 = 85 : 15 to 100 : 0
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flow rate: 1.0 mL/min
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Development of UV/Vis spectroscopy-based assay for MurG. The lipid 
II analogue, 9-C55 are readily extracted with n-BuOH and the 
contaminated UDP-GlcN-C6-FITC (8) in the organic phase can be 
removed by washing with a 1 : 1 mixture of saline and 0.2 M mannitol 
(an 8-washing solution). Because separation of lipid I and lipid 
II analogues are not necessary in this assay, the fluorescence in 
nBuOH extract of MurG reaction was monitored via ultraviolet-
visible (UV-Vis) spectrometry (excitation of 485nm, emission of 
528nm); the UV-Vis-based assay was performed at a sufficiently 
high concentration of Park’s nucleotide (10) or Park's nucleotide-
N-C6-dansylthiourea (1e) (45-75 M) for UV-Vis spectrometry and 
enough concentrations of UDP-GlcN-C6-FITC (8) that fulfill the Km 
value (e.g., 135-375 M). Progress of the MurG-catalyzed reaction 
of 2e-C55 was monitored for 3 h. As shown in Figure 6A, an increase 
in fluorescence signal was observed in a time-dependent manner 
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that was well-correlated to the yield curve obtained via the HPLC 
method (Figure 6B). A UV-Vis-based MurG assay developed here was 
Figure 6. Correlation of biotransformation of C55-lipid II-FITC 
determined via UV-Vis and HPLC. 
A. Time-course experiments of biotransformation of C55-lipid II-FITC (11-C55)
or C55-lipid II-N-C6-dansyl-FITC (9-C55) via UV-Vis
B. Time-course experiments of biotransformation of C55-lipid II-FITC (11-C55)
or C55-lipid II-N-C6-dansyl-FITC (9-C55) via HPLC
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Figure 7. Dose-response curves of two inhibitors evaluated via a 
UV-Vis-based MurG assay.
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validated by demonstrating the inhibition of MurG activity by two 
antibiotics, ramoplanin A2 (12) and nikkomycin Z (13). Generation 
of 9-C55 was inhibited by both ramoplanin A2 and nikkomycin Z in a 
dose-dependent manner (Figure 7). The IC50 values of ramoplanin A2 
against MsmegMurG and HyMurG were determined to be 25.5 and 22.4 
M by dose-response curves via UV-Vis spectrometry (Figure 7). 
These data obtained via a new assay method are close to the IC50 
values (20-50 M) reported by the other groups.39-41 In our 
preliminary screening of in-house library molecules, we found that 
nikkonmycin Z, an inhibitor of chitin synthases, shows a 
competitive inhibitory activity against MurG. The IC50 values of 
nikkonmycin Z against MsmegMurG and HyMurG were 9.5 and 8.7 M, 
respectively. It was determined that DMSO did not inhibit the MurG 
assays at 5% (v/v) concentrations. However, inhibition of the 
reactions was started at 10% (v/v) of DMSO; approximately 50% of 
the enzyme activity was reduced at this concentration (see SI).
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Figure 8. Structures of positive- and negative-controls.
A microplate-based assay for MurG. The microplate-based assay were 
performed with Park’s nucleotide (10) under the condition 
established in Figure 4A (all substrate used are >Km 
concentrations). The microplate-based MurG assay via UV/Vis 
spectroscopy was validated by demonstrating screening of a 
collection of molecules including positive (ramoplanin A2, 
nikkomycin Z)-, negative (selective MraY and WecA inhibitors)- 
controls in triplicate with 96-well plates. In these screenings, 
purified HyMurG was applied. All compounds were screened at three 
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different conditions (10, 50, and 100 M). Each plate contained 
four control wells: the first one with the denatured MurG (heated 
at 100 oC for 2 min.), the second one without MurG, the third one 
addition of 30% (v/v) of DMSO and the fourth one with ramoplanin 
A2 (12) at 50 M. Under the assay conditions, seven molecules 
including nikkomycin Z (13) were identified as MurG inhibitors. 
The identified MurG inhibitors were confirmed by the HPLC-based 
assays at 0.1, 1, 10, 50, and 100 M concentrations, being created 
dose-response curves to obtain their IC50 value (Table 3). Two MurG 
inhibitors (ToXa-1 (15) and PyDT-1 (16) reported previously (Hu et 
al. 2004)42 displayed MurG inhibitory activity with the IC50 value 
of 2.2 and 2.7 M, respectively.43 (Figure 8). As described above, 
nikkomycion Z (13) showed a completive inhibitor of MurG with the 
IC50 value of 8.6 M. On the other hand, another chitin synthase 
inhibitor, polyoxin D (14) exhibited a weak MurG inhibitory 
activity (IC50 50.8 M). Ristocetin A (17) was identified as a 
strong inhibitor of MurG (IC50 0.96 M against HyMurG). Although 
moenomycin A (18), a transglycosylase inhibitor, was reported to 
inhibit MurG (IC50 10.6 M) via a coupled assay using MurG-pyruvate 
kinase-lactic dehydrogenase (Liu et al. 2003),23 our assay method 
did not cause a false-positive result; moenomycin A did not inhibit 
MurG function at 50-100 M. Vancomycin (19) is an antibiotic that 
has frequently applied as a positive-control in several coupling 
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assays including the method developed by the Wong group.23 In our 
studies, it was demonstrated that vancomycin hampers the 
extraction of the lipid I and lipid II derivatives with n-BuOH, 
making pseud-inhibitory activity in a concentration independent 
manner (entry 9 in Table 3). The other molecules including 
MraY/MurX (tunicamycins (20), APPU (21),44,45 and capuramycin 
(22)),46,47 WecA (O-methylcapuramycin (23)48), triflumuron (24), and 
nisin did not inhibit the lipid II formation at 50-100 M 
concentrations. Importantly, the inhibitory activities of the MurG 
inhibitors identified using HyMurG were well-correlated to those 
against MsmegMurG (Table 3).
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Table 3. MurG assay against a collection of positive- and 
negative-controls.
Antimycobacterial activity of ristocetin A. The glycopeptide 
antibiotics such as vancomycin (17) display antibacterial activity 
by forming hydrogen bondings between the glycopeptide aglycones 
and the L-Lys-D-Ala-D-Ala segment of the peptidoglycan precursors 
(e.g., lipid II) located in Gram-positive bacterial cell 
membrane.49-53 While vancomycin and ristocetin A are structurally 
similar, the mode of action of ristocetin A is different from that 
of vancomycin;54 the interaction of ristocetin A with the L-Lys-D-
Ala-D-Ala segment of lipid II is very weak as demonstrated by our 
Compound
HthermMurG (MsmegMurG) inhibition (%)a
50 M
IC50 (M)
HyMurGb
Ramoplanin A2 (12) 100 (100) 22.4
Nikkomycin Z (13) 50 (45) 8.7
Polyoxin D (14) 48 (48)
ToXa-1 (15)
entry
1
2
3
4
5 PyDT-1 (16) 55 (60)
100 M
100 (100)
95 (93)
50 (45)
98 (100)
10 M
0 (0)c
33 (35)
34 (40)
46 (48)
a 1) Reaction conditions: CHAPS (20 wt%): 1.25 L, -mercaptoethanol (50 mM): 5 L, MgCl2 (0.5 M): 5L, KCl (2 M): 5L, Park's nucleotide (10 for UV-Vis- based
assays, 2 mM) or Park's nucleotide-N-C6-dansyl (1e-C55, for HPLC-based assays, 2 mM): 1.88 L, C55-P (4 mM): 2.81L (3 eqv),
HyMraY (125 M): 1 L, after 1h, UDP-GluN-C6-FITC (8, 10 mM): 1.88 L (5 eqv), inhibitor molecule (0.1-100 M), HyMurG (8.3 g/mL): 5 L or P-60-M. smegmatis
(1 mg/L, 10-30 L), for 1 h at 37 oC. Work-up: n-BuOH (150 L), a 1:1 mixture of saline/0.2 M mannitol. Analyses: UV-Vis method
b Each experiment was performed two-three times, and the average IC50 values were summarized. Analyses: HPLC-based method
c The lipid I and lipid II derivatives formed complexes with vancomycin (19), causing pseudo-inhibitory activity in a concentration independent manner.
IC50 (M)
MsmegMurGb
IC50 (M)
MsmegMraYb
23.5 >100
9.5 >100
50.8 55.0 >100
65 (68) 98 (100)51(50) 2.2 2.0 >100
2.7 3.5 >100
Ristocetin A (17) 70 (65) 0.96
Moenomycin A (18) 0 (0) >100
Vancomycin (19) 55 (67)c
Tunicamycin (20)
7
8
9
10
11 APPU (21) 0 (0)
95 (93)
12 (15)
50 (58)c
0 (0)
55 (58)
0 (0)
59 (60)c
0 (0)
1.4 0.81
>100 >100
0 (0) 0 (0)0 (0) >100 >100 2.9
>100 >100 0.085
ND ND ND
Capuramycin (22) 0 (0) >100
O-Methylcapuramycin (23) 0 (0)
Triflumuron (24)
13
14
15
16 Nisin (not shown in Fig. 7) 0 (0)
0 (0)
0 (0)d
2 (5)
0 (0)
0 (0)
0 (0)
>100 0.13
0 (0) 0 (0)0 (0) >100 >100 >100
>100 >100 >100
>100 >100 >100
17 DMSO 0 (0) 0 (0)0 (0) ND ND ND
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MurG assay methods (Table 3). Kinetic studies of inhibition of 
HyMurG in the presence of ristocetin A (5 M) revealed that 
ristocetin A competes for the UDP-GlcNAc binding-site (Figure 9). 
Ristocetin A is also a strong inhibitor of MurX (IC50 0.81 M 
against MsmegMurX, see SI) via a mechanism of non-competitive 
inhibition against Park’s nucleotide and prenyl-P. Recognition and 
complexation of the L-Lys-D-Ala-D-Ala portion of lipid II have been 
the interest of ristocetin A and other glycopeptide antibiotics.55 
Figure 9.  Michaelis-Menten plots for MurG-catalyzed formation 
of C55-lipid II-N-C6-dansylthiourea (3e-C55) in the presence and 
absence of ristocetin A.
0 50 100 150
0.0
0.2
0.4
0.6
0.8
A. MsmegMurG kinetics in the presence of ristocetin A at different
concentrations of 2e-C55
C55-lipid I-N-C6-dansylthiourea
(2e-C55, M)
V
( M
/m
in
)
No ristocetin A
Vmax = 0.83  0.08 M/min
Km = 35  11 M
ristocetin A (5 M)
Vmax = 0.46  0.02 M/min
Km = 35  5.3 M
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B. MsmegMurG kinetics in the presence of ristocetin A at different
concentrations of UDP-GlcNAc
UDP-GlcNAc (M)
V
( M
/m
in
)
No ristocetin A
Vmax = 0.68  0.04 M/min
Km = 44  9.8 M
ristocetin A (5 M)
Vmax = 0.66  0.01 M/min
Km = 70  5.3 M
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To the best of our knowledge, a molecule that has dual inhibitory 
activities against MurG and MraY/MurX at such a low concentrations 
has never been reported.
Antimycobacterial activity of the MurG inhibitors identified in Table 3 were examined against 
M. smegmatis (ATCC607) and M. tuberculosis (H37Rv). Nikkomycin Z (13), polyoxin D (14), 
ToXa-1 (15), and PyDT-1 (16) did not inhibit growth of these bacteria even at 50 g/mL 
concentration. A moderate MurG inhibitor, ramoplanin A2 (12) has antimycobacterial activity with 
the MIC level of 3.25-12.5 g/mL. Ristocetin A (17) exhibited strong bactericidal activity against 
Mycobacterium spp. with MIC below 0.35 g/mL. ToXa-1 exhibited cytotoxicity against Vero 
cell with the IC50 value of 12.5 g/mL. All other MurG inhibitors identified in Table 3 did not 
show cytotoxicity against Vero cells at 100 g/mL concentration (Table 4).
Table 4.  MIC of MurG inhibitors (12-17) against Mycobacterium 
spp.
Compound
M. smegmatis (ATCC607)a
MIC (g/mL)
Ramoplanin A2 (12) 3.25
Nikkomycin Z (13) >50.0
Polyoxin D (14)
ToXa-1 (15)
entry
1
2
3
4
5 PyDT-1 (16)
a M. smegmatis (ATCC607) was cultured with 7H9 containing 0.5% tween 80. The bacterial culture in a 96-well plate
treated or non-treated with compounds was incubated for 3 days at 37 oC in a static incubator. Resazurin (0.01%, 20
L) was added to each well and incubated at 37 oC for 4h. The MIC values were determined according to NCCLS
method (pink = growth, blue = no visible growth).
b M. tuberculosis (H37Rv) was cultured with 7H9 containing OADC. The culture was incubated for 14 days.
c Kidney epithelial cells extracted from an African green monkey (ATCC).
M. tuberculosis (H37Rv)b
MIC (g/mL)
Vero cellc
(g/mL)
6.25-12.5 >100
>50.0 >100
>50.0 >50.0 >100
>50.0 >50.0 12.5
>50.0 >50.0 >100
Ristocetin A (17) <0.39
Rifampicin 1.58
Ethambutol
7
8
9
10
11 Vancomycin (19)
0.5 >100
0.17 >100
0.78 0.16 >100
3.12 12.5 >100
0.39 0.78 >100
INH
12 Tunicamycin (20) 6.25-12.5 12.5 1.56
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Structural comparison between MurG proteins of Mycobacterium spp. 
and Hydrogenivirga sp. We demonstrated that MurG of Hydrogenivirga 
sp. is a convenient surrogate for MsmegMurG for screening of 
antimycobacterial MurG inhibitors. BLAST search [Altschul et al. 
1990]56 of MurG enzymes of M. smegmatis (MC2 155), Hydrogenivirga 
sp. (128-5-R1-1), and E. coli (K-12) against M. tuberculosis 
(H37Rv) revealed that MurG between M. tuberculosis and M. 
smegmatis: 84% similarity / 76% identity, Hydrogenivirga sp. and 
M. tuberculosis: 42% similarity / 26% identity, and E. coli and M. 
tuberculosis: 53% similarity / 39% identity (see SI). Although 
moderate primary sequence similarity between Hydrogenivirga sp. 
and M. smegmatis or M. tuberculosis, we confirmed that inhibitory 
response of the inhibitor molecules against MurG is similar among 
those obtained from Mycobacterium spp. and Hydrogenivirga sp. MurG 
is tightly associated with peripheral membrane. Although MurG of 
E. coli was successfully crystallized and X-ray diffraction 
experiments were successfully carried out (Ha et al. 2000),57 our 
studies suggested that purification of MurG enzymes of 
Mycobacterium spp. remains a very challenging task. Thus, applying 
thermally stable HyMurG has significant advantage in context from 
reliable and practical enzyme sources for assay screenings. In 
order to understand correlation of MurG inhibitory activity across 
the bacterial species, we constructed a homology model of HyMurG 
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based on EcMurG (PDB: 1F0K). Albeit a lower sequence identity (31%) 
between two MurG enzymes, no apparent difference in overall fold 
was observed (Figure 10A). Some structural deviations were 
observed in the loop regions, but all hydrophobic segments 
associated with the putative active site are highly conserved. 
Multiple sequence alignment of MurG homologs revealed high 
conservation in the active site (Figure 10B).
Figure 10.  Conservation of MurG homologs. A: Structural models 
of MurG with E. coli (PDB ID: 1F0K) aligned to a homology model 
of MurG from Hydrogenivirga sp. HyMurG colored in green and 
EcMurG in gray. Putative active site is magnified in the inset 
with important catalytic residues as sticks, numbering based on 
EcMurG. Homology model was created in SWISS-MODEL [Waterhouse et 
al. 201858 using EcMurG (PDB ID: 1F0K) chain B as a template. 
Figure was generated using PyMOL (Version 2.2.3, Schrödinger, 
LLC, Portland, OR, USA)59. B: Alignment of MurG sequences from 
EcMurG, HyMurG, and MtbMurG highlighting residues from A. 
Alignment made using T-Coffee and ESPript [Tommaso et al. 2011; 
Robert et al. 2014]60,61.
A.
B.
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CONCLUSIONS
We have studied the fluorescent probe-conjugated substrates for 
MraY/MurX and MurG enzymes. To date, a very few number of Park’s 
nucleotide fluorescent probes have been demonstrated in their 
transformations to the corresponding lipid II derivatives with the 
purified enzymes. MraY/MurX- and MurG-catalyzed biotransformation 
with the Park’s nucleotide fluorescent probe, 1e, yields the lipid 
II-fluorescent, 3e-C55, in very high yield. The MurG assay protocols 
developed here do not require separation of the reaction products 
via specific biopolymer(s) that require extensive washing 
processes. In contrast, our assays developed herein take advantage 
of a strong hydrophobicity of the MraY/MurX and MurG products. A 
washing condition (a 1 : 1 mixture of saline and 0.2 M mannitol) 
can prevent a micelle formation of the lipid I and lipid II 
derivatives, retaining these products in the BuOH phase and 
solubilizing the donors, UDP-GlcNAc or UDP-GlcN-C6-FITC (8) in the 
aqueous phase. Importantly, the Park’s nucleotide fluorescent 
probe, 1e, can readily be synthesized from Park’s nucleotide (10). 
Conveniently, the intact Park’s nucleotide can be applied to the 
MurG assays with 8. The microplate-based MurG assays using 10 and 
Page 34 of 64
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
35
8 summarized in Figure 4A and Figure 6 show good correlations with 
the assays via HPLC, and could be applicable to HTS. The HPLC-
based MurG assays summarized in Figure 4B can monitor both lipid 
I and lipid II derivative simultaneously at different wavelengths, 
thus, false results will not be generated in these assays. The 
membrane fraction (P-60) prepared from M. smegmatis (ATCC607) is 
a convenient surrogate of MtbMurX and MtbMurG. We experimentally 
proved that the purified MurG of Hydrogenivirga sp. can serve as 
a reliable and alternative source of MsmegMurG; IC50 values 
obtained with HyMurG are very close to those with P-60 of M. 
smegmatis. HyMraY and HyMurG can keep at -80 oC for over a year 
without loss of activity and tolerate to multiple freeze and thaw 
cycles. Therefore, combination of the unique donor/acceptor 
substrates (1e and 8) and enzyme sources (HyMraY and HyMurG) will 
provide robust MurG assay screenings. In preliminary screening of 
a collection of small molecules, ristocetin A (17) shows strong 
MurG inhibitory activity by competing with UDP-GlcNAc. Ristocetin 
A is also a strong MraY/MurX inhibitor, whereas, vancomycin (19) 
does not bind both MraY/MurX and MurG enzymes. Antimycobacterial 
activity of ristocetin A is stronger than that of vancomycin. Our 
studies imply that strong antimycobacterial activity of ristocetin 
A cannot be explained solely by the binding ability to the L-Lys-
D-Ala-D-Ala portion of lipid II. Ristocetin A has about 3.0 times 
less binding affinity against the L-Lys-D-Ala-D-Ala mimetic than 
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that of vancomycin.53 It has never been reported previously that a 
single molecule inhibits both MraY/MurX and MurG at low 
concentrations. Ramoplanin A2 with a larger molecular weight (Mw 
=2,554) is widely accepted as a MurG inhibitor with a membrane 
disrupting activity.41 Ramoplanin’s MurG inhibition is very weak, 
thus, a strong antibacterial MurG inhibitor will be a useful lab 
tool as well as a lead compound for developing new MurG inhibitors. 
We have been attempting to generate ristocetin A resistant mutants 
of M. smegmatis (ATCC 607) to obtain insights into the mode of 
antimycobacterial activity of ristocetin A. Appropriate chemical 
modifications of ristocetin A are known to attenuate thrombocyte 
aggregation,62 making ristocetin A analogues as new TB drug leads 
to combat MDR strains. SAR of ristocetin A against drug resistant 
Mtb and platelet aggregation activity and screening date for a 
large library molecule will be reported elsewhere.
EXPERIMENTAL SECTION
All experimental detail are provided in Supporting Information
Cloning, expression, and purification
Expression and purification of HyMraY: The gene mraY of 
Hydrogenivirga sp.128-5-R1-1 was cloned with an N-terminal His6 
tag into a pET22b vector. The plasmid was transformed and expressed 
in E. coli NiCo21(DE3) pLEMO competent cells. The proteins were 
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purified using a nickel-affinity, cation exchange, and size 
exclusion chromatography. The final storage buffer was 20 mM HEPES 
pH 7.5, 100 mM NaCl, 10% glycerol, 5 mM -mercaptoethanol, 0.15% 
decyl -D-maltopyranoside. 
Expression and purification of HyMurG: The gene murG of 
Hydrogenivirga sp.128-5-R1-1 was cloned with an N-terminal His6 
tag into a pET33b vector. The plasmid was transformed and expressed 
in E. coli NiCo21(DE3) competent cells. The proteins were purified 
using a cobalt-affinity and size exclusion chromatography. The 
final storage buffer was 20 mM Tris pH 7.5, 150 mM NaCl, 10 % 
glycerol, 0.15 % decyl -D-maltopyranoside, and 5 mM -
mercaptoethanol.
Preparation of P-60 membrane fraction from M. smegmatis 
(ATCC607): The cells were harvested by centrifugation followed by 
washing with saline and buffer A (50 mM potassium phosphate, 5 mM 
MgCl2, 5 mM DTT, 10% glycerol, pH 7.2). The washed cell pellets 
were suspended in buffer A and disrupted by sonication on ice-
bath. The resulting suspension was centrifuged at 4,700 xg for 15 
min at 4 °C. The supernatant was centrifuged at 25,000 xg for 20 
min at 4 °C. The supernatant was subjected to ultracentrifugation 
at 100,000 xg for 1 h at 4 °C. The supernatant was discarded and 
the pellet containing the membrane was suspended in Tris buffer 
(pH 7.5, 1 mg/1 L). 
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Enzymatic assay procedures
Protocol A (in Figure 3): Park’s nucleotide-Nε-C6-dansylthiourea 
(1e) (2 mM stock solution, 1.88 μL), CHAPS (20%, 1.25 μL), -
mercaptoethanol (50 mM, 5 μL), MgCl2 (0.5 M, 5 μL), KCl (2 M, 5 
μL), and C55-phosphate dissolved in NaHCO3 (50 mM) : DMSO (1 : 4) 
(4 mM, 2.81 μL) were placed in a 1.5 mL Eppendorf tube. To a 
reaction mixture, HyMraY (4.18 mg/mL, 1 μL) was added (total volume 
of reaction mixture: 50 μL adjust with Tris buffer (50 mM, pH = 
8.0)). The reaction mixture was incubated for 1 h at 37 oC. To a 
reaction mixture, inhibitor molecule (0 - 100 g/mL in Tris 
buffer), UDP-GlcNAc (10 mM stock solution, 1.88 μL), and P-60 (1 
mg/μL, 30 μL) or HyMurG (5.2 mg/mL, 5 μL) were added. The reaction 
mixture was incubated for 1 h at 37 oC, and quenched with water 
saturated n-butanol (150 μL). Two phases were mixed via vortex for 
2 min and centrifuged at 25,000 xg for 10 min. The upper n-butanol 
phase was assayed via reverse-phase HPLC. The n-butanol phase (30 
μL) was injected into HPLC (solvent: a gradient elution of 
CH3OH/0.05 M aq. NH4HCO3 = 70 : 30 to 100 : 0 over 30 min; UV: 350 
nm; flow rate: 1.0 mL/min; column: Luna 5μm C8, 100 A, 250 x 4.60 
mm), and the area of the peak for C55-lipid II-Nε-C6-dansyl-FITC 
was quantified to obtain the IC50 value. The IC50 values were 
calculated from plots of the percentage product inhibition versus 
the inhibitor concentration.
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Protocol B (in Figure 3): Park’s nucleotide-Nε-C6-dansylthiourea 
(1e) (2 mM stock solution, 1.88 μL), CHAPS (20%, 1.25 μL), -
mercaptoethanol (50 mM, 5 μL), MgCl2 (0.5 M, 5 μL), KCl (2 M, 5 
μL), and C55-phosphate dissolved in NaHCO3 (50 mM) : DMSO (1 : 4) 
(4 mM, 2.81 μL) were placed in a 1.5 mL Eppendorf tube. To a 
stirred reaction mixture, P-60 (1 mg/μL, 30 μL) was added (total 
volume of reaction mixture: 60 μL adjust with Tris buffer (50 mM, 
pH = 8.0)). The reaction mixture was incubated for 1 h at 37 oC. 
To a reaction mixture, tunicamycin (10 mg/mL stock solution, 0.25 
μL) was added, and inhibitor molecule (0 - 100 g/mL in Tris 
buffer) and UDP-GlcNAc (10 mM stock solution, 1.88 μL) were added. 
The reaction mixture was incubated for 1 h at 37 oC, and quenched 
with water saturated n-butanol (150μL). Two phases were mixed via 
vortex for 2 min and centrifuged at 25,000 xg for 10 min. The upper 
n-butanol phase was assayed via reverse-phase HPLC. See, Protocol 
A for the analyses. 
UV/VIS spectroscopy-based assay (non-microplate MurG assay): 
Park’s nucleotide-Nε-C6-dansylthiourea (1e) (2 mM stock solution, 
1.88 μL), CHAPS (20%, 1.25 μL), -mercaptoethanol (50 mM, 5 μL), 
MgCl2 (0.5 M, 5 μL), KCl (2 M, 5 μL), and C55-phosphate dissolved 
in NaHCO3 (50 mM) : DMSO (1 : 4) (4 mM, 2.81 μL) were placed in a 
1.5 mL Eppendorf tube. To a stirred reaction mixture, HyMraY (4.18 
mg/mL, 1 μL) was added (total volume of reaction mixture: 50 μL 
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adjust with Tris buffer (50 mM, pH = 8.0)). The reaction mixture 
was incubated for 1 h at 37 oC. To a reaction mixture, inhibitor 
molecule (0 - 100 g/mL in Tris buffer), UDP-GlcN-C6-FITC (10 mM 
stock solution, 1.88 μL), and P-60 (1 mg/μL, 30 μL) or HyMurG (5.2 
mg/mL, 5 μL) were added. The reaction mixture was incubated for 1 
h at 37 oC, and quenched with water saturated n-butanol (150μL). 
Two phases were mixed via vortex for 2 min and centrifuged at 
25,000 xg for 10 min. The n-butanol phase was washed with a 1 : 1 
mixture of saline and 0.2 M mannitol (50 μL, thrice) and the washed 
n-butanol phase (20 μL) was transferred to a 384 well black plate 
and fluorescence was measured at an excitation of 485 nm and 
emission of 528 nm. The IC50 values were calculated from plots of 
the percentage product inhibition versus the inhibitor 
concentration.
Microplate MurG assay: The assay was performed in 96-well plates. 
The reaction mixture contained park’s nucleotide-Nε-C6-
dansylthiourea (1e) (2 mM stock solution, 1.88 μL), CHAPS (20%, 
1.25 μL), -mercaptoethanol (50 mM, 5 μL), MgCl2 (0.5 M, 5 μL), 
KCl (2 M, 5 μL), C55-phosphate dissolved in NaHCO3 (50 mM) : DMSO 
(1 : 4) (4 mM, 2.81 μL), and HyMraY (4.18 mg/mL, 1 μL) (total 
volume of reaction mixture: 50 μL adjust with Tris buffer (50 mM, 
pH = 8.0)). The reaction mixture was incubated for 1 h at 37 oC. 
To a reaction mixture, inhibitor molecule (0 - 100 g/mL in Tris 
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buffer), UDP-GlcN-C6-FITC (10 mM stock solution, 1.88 μL), and 
HyMurG (5.2 mg/mL, 5 μL) were added. The reaction mixture was 
incubated for additional1 h at 37 oC. The reaction was quenched by 
adding water-saturated n-butanol (150 μL) and thoroughly mixed 20 
times using a multichannel pipette. The upper phase was transferred 
to another well and washed with a 1 : 1 mixture of saline and 0.2 
M mannitol (50 μL). Two phases were thoroughly mixed and the upper 
phase was washed with a 1 : 1 mixture of saline and 0.2 M mannitol 
(50 μL) (repeated twice). The upper phase (20 μL) was transferred 
to a 384 well black plate and fluorescence was measured at an 
excitation of 485 nm and emission of 528 nm. 
Synthesis and characterization of representative molecules
Park’s nucleotide-N-C6-dansylthiourea (1e): To a solution of 
Park’s nucleotide (10) (6.3 mg, 5.5 mol) and SuO-C(O)O-(CH2)6-
NHCOCF3 (5.8 mg, 0.017 mmol) in MeCN (0.5 mL) was added Et3N (3.9 
L, 0.028 mmol). After being stirred for 12 h at r.t., the solution 
was concentrated under reduced pressure and the resulting product 
was dried under high vacuum. To a solution of the crude product in 
THF (0.5 mL) was added 0.2 mL of aq. LiOH (2.3 mg, 0.055 mmol). 
After being stirred for 3 h at r.t., the reaction mixture was 
filtered. The crude product was purified by reverse phase HPLC 
[column: HYPERSIL GOLD™ (175 Å, 12 m, 150 x 20 mm), solvents: 0 
: 100 CH3CN : 0.05 M aq. NH4HCO3 for 5 min then 5 : 95 CH3CN : 0.05 
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M aq. NH4HCO3 for 10 min then 10 : 90 CH3CN : 0.05 M aq. NH4HCO3 for 
10 min, flow rate: 4.0 mL/min, UV: 254nm]. To a solution of the 
product and NaHCO3 (4.6 mg, 0.055 mmol) in a 4 : 1 mixture of THF 
and H2O (0.5 mL) was added 4-(dansylamino)phenyl isothiocyanate 
(10.5 mg, 0.028 mmol). After being stirred for 4 h at r.t., the 
reaction mixture was filtered. The filtrate was purified by reverse 
phase HPLC [column: Phenomenex Luna (100 Å, 10 m, C18, 250 x 10 
mm), solvents: 10 : 90 CH3CN : 0.05 M aq. NH4HCO3 for 5 min then 20 
: 80 CH3CN : 0.05 M aq. NH4HCO3 for 10 min then 30 : 70 CH3CN : 0.05 
M aq. NH4HCO3 for 10 min, flow rate: 3.0 mL/min, UV: 350nm] to 
afford 1e (6.4 mg, 70% overall, retention time: 24.7 min): 1H NMR 
(400 MHz, Deuterium Oxide) δ 8.55 (d, J = 8.2 Hz, 1H), 8.30 (d, J 
= 8.2 Hz, 1H), 8.15 (d, J = 7.4 Hz, 1H), 7.87 (d, J = 8.1 Hz, 1H), 
7.32 (d, J = 7.2 Hz, 1H), 7.07 (s, 1H), 6.87 (s, 4H), 5.93 (ddd, 
J = 3.8, 1.6, 0.9 Hz, 1H), 5.89 (d, J = 8.0 Hz, 1H), 5.41 (dd, J 
= 7.7, 3.2 Hz, 1H), 4.30 (d, J = 3.3 Hz, 3H), 4.28 – 4.01 (m, 10H), 
3.92 – 3.87 (m, 1H), 3.82 – 3.77 (m, 2H), 3.74 – 3.70 (m, 1H), 
3.61 – 3.57 (m, 1H), 3.39 – 3.32 (m, 2H), 2.98 – 2.90 (m, 2H), 
2.80 (s, 6H), 2.24 – 2.18 (m, 4H), 2.14 – 2.09 (m, 3H), 1.95 (s, 
3H), 1.80 – 1.76 (m, 1H), 1.62 – 1.43 (m, 4H), 1.37 (d, J = 7.5 
Hz, 3H), 1.34 (d, J = 7.1 Hz, 3H), 1.28 (d, J = 7.0 Hz, 3H), 1.26 
(d, J = 6.9 Hz, 3H), 1.17 – 1.11 (m, 4H), 0.86 – 0.78 (m, 4H); 
HRMS (ESI+) m/z calcd for C66H96N13O30P2S2 [M + H] 1676.5303, found: 
1676.5322.
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Lipid I (7). Synthesis of 5: To a solution of 4 (0.33 g, 0.46 
mmol) in a 9:5:1 mixture of MeOH, formic acid and H2O (15 mL) was 
added Pd-C (0.65 g). The reaction solutionn was stirred under 
hydrogen atmosphere (400 psi) for 17 h. The reaction mixture was 
filtrated and the residue was concentrated under reduced pressure. 
The crude product was purified by silica gel column chromatography 
(EtOAc/MeOH = 90/10) to afford the free-alcohol (0.26 g, 91%). To 
a solution of the anomeric-free alcohol (0.21 g, 0.34 mmol) and 5-
(ethylthio)-1H-tetrazole (0.13 g, 1.0 mmol) in CH2Cl2 (3.4 mL) was 
added dibenzyl N,N-diisopropylphosphoramidite (0.29 mL, 0.86 mmol) 
at 0 oC. After 2 h at 0 oC, the reaction was quenched with sat. 
NaHCO3 solution and the mixture was separated. The aqueous layer 
was extracted with CHCl3 and the combined organic layer was dried 
over Na2SO4, and evaporated. 70% aq. tert-butyl hydroperoxide (0.48 
mL, 3.4 mmol) was added to a solution of the residue and NaHCO3 
(58 mg, 0.69 mmol) in THF (3.4 mL) at 0 oC. After 30 min. at r.t., 
the reaction was quenched with aq. Na2S2O3 and the mixture was 
extracted with CHCl3 and the combined organic layer was dried over 
Na2SO4, and evaporated. The residue was purified by silica gel 
column chromatography (EtOAc/MeOH = 90/10) to afford 5 (0.28 g, 
93% for 2 steps). 1H NMR (400 MHz, Chloroform-d) δ 7.92 (dd, J = 
8.4, 1.3 Hz, 2H), 7.68 (tt, J = 7.4, 1.3 Hz, 1H), 7.61 – 7.56 (m, 
2H), 7.39 – 7.32 (m, 10H), 6.73 (d, J = 7.0 Hz, 1H), 6.12 (d, J = 
9.0 Hz, 1H), 5.62 (dd, J = 5.8, 3.2 Hz, 1H), 5.14 – 4.97 (m, 6H), 
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4.45 (td, J = 6.2, 1.3 Hz, 2H), 4.33 (ddt, J = 10.6, 9.0, 3.1 Hz, 
1H), 4.19 (t, J = 7.2 Hz, 1H), 4.10 (dd, J = 13.1, 4.6 Hz, 1H), 
3.92 (d, J = 13.8 Hz, 1H), 3.89 (d, J = 9.8 Hz, 1H), 3.50 – 3.41 
(m, 3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.75 (s, 3H), 1.30 (d, J = 
6.9 Hz, 3H), 1.29 (d, J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
171.93, 171.51, 170.63, 170.60, 169.12, 139.05, 134.11 (2C), 
129.47 (2C), 129.04 (2C), 128.80 (4C), 128.16 (2C), 128.08 (4C), 
96.85, 96.78, 78.37, 70.15, 70.03, 69.98, 68.65, 61.45, 58.07, 
54.84, 52.92, 52.85, 47.92, 22.97, 20.79, 20.65, 18.62, 17.00; 31P 
NMR (162 MHz, CDCl3) δ -2.39 ; HRMS (ESI+) m/z calcd for 
C40H49N2NaO16PS [M + Na] 899.2438, found: 899.2412. Synthesis of 6: 
To a solution of 6 (78 mg, 0.089 mmol) in CH2Cl2 (0.45 mL) was 
added DBU (15 L, 0.098 mmol). After stirring the solution for 1 
h at r.t., the reaction was quenched with 1 M aq. HCl and the 
mixture was separated. The aqueous layer was extracted with EtOAc 
and the combined organic layer was dried over Na2SO4. After 
concentration under reduced pressure, GOx (41 mg, 0.18 mmol) and 
EDCI (34 mg, 0.18 mmol) were added to a solution of the crude 
product, tetrapeptide (0.10 g, 0.18 mmol) and NaHCO3 (38 mg, 0.45 
mmol) in 24:1 solution of DMF and H2O (1.0 mL). After stirring the 
solution for 2 h at r.t., the reaction was added 9:1 solution of 
chloroform and methanol (5 mL). The solution was washed with aq. 
NH4Cl and aq. NaHCO3, and the organic layer was dried over Na2SO4. 
Concentration under reduced pressure followed by purification by 
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silica gel column chromatography (EtOAc/MeOH/Et3N = 93/7/0.5 - 
90/10/0.5) afforded 99 mg (90% for 2 steps) of 7. 1H NMR (400 MHz, 
Chloroform-d) δ 7.75 (t, J = 5.8 Hz, 1H), 7.60 (d, J = 7.7 Hz, 
1H), 7.38 – 7.30 (m, 10H), 7.15 (d, J = 5.8 Hz, 1H), 7.10 (d, J = 
8.5 Hz, 1H), 6.88 (d, J = 8.7 Hz, 1H), 5.64 (dd, J = 5.9, 3.2 Hz, 
1H), 5.06 (ddd, J = 9.2, 8.4, 3.0 Hz, 6H), 4.54 – 4.30 (m, 7H), 
4.24 (quin, J = 6.9 Hz, 1H), 4.15 – 4.09 (m, 2H), 3.91 (d, J = 
10.6 Hz, 2H), 3.70 (s, 3H), 3.68 (s, 3H), 3.69 – 3.66 (m, 1H), 
3.59 (t, J = 9.9 Hz, 1H), 3.31 (q, J = 6.5 Hz, 2H), 3.10 (q, J = 
7.3 Hz, 1H), 2.38 – 2.13 (m, 4H), 2.07 (s, 3H), 1.99 (s, 3H), 1.78 
(s, 3H), 1.58 (tt, J = 13.5, 6.2 Hz, 2H), 1.43 (d, J = 7.0 Hz, 
3H), 1.38 (d, J = 7.4 Hz, 3H), 1.37 (d, J = 7.3 Hz, 3H), 1.29 (d, 
J = 6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.32, 173.24, 172.73, 
172.60, 172.18, 172.02, 171.94, 171.05, 170.57, 169.26, 157.45 (q, 
J = 36.8 Hz), 129.00 (2C), 128.76 (4C), 128.63, 128.56, 128.09 
(4C), 70.02, 69.98, 68.63, 61.46, 53.82, 53.09, 53.01, 52.48, 
52.29, 50.76, 50.27, 49.12, 48.03, 45.85, 39.42, 31.40, 31.16, 
29.66, 28.16, 27.58, 22.78, 22.36, 20.79, 20.61, 18.54, 17.82, 
17.64, 17.22, 8.57; 31P NMR (162 MHz, CDCl3) δ -2.72; HRMS (ESI+) 
m/z calcd for C53H74F3N7O21P [M + H] 1232.4628, found: 1232.4646. 
Synthesis of 7: To a solution of 6 (9.2 mg, 7.5 mol) in MeOH (10 
mL) was added 10% Pd-C (18 mg). After being stirred the reaction 
mixture under hydrogen atmosphere (using double-fold balloons) for 
1 h, Et3N (0.5 mL) was added to the mixture. After 1 h, the catalyst 
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was filtered through a pad of Celite. The filtrate was concentrated 
under reduced pressure and the resulting product was dried under 
high vacuum. To a solution of the crude product in a 3:1 mixture 
of THF and DMF (0.5 mL) was added CDI (3.6 mg, 0.023 mmol). After 
being stirred for 3 h at r.t., MeOH (20 L) was added to the 
reaction mixture. After 30 min, the solution was evaporated, 
concentrated under high vacuum, and the resulting product was 
dried. To a solution of the crude product in a 3:1 mixture of THF 
and DMF (0.5 mL) was added C55-P-NH4 (5.3 mg, 6.0 mol). After 48 
h at r.t., the reaction mixture was filtered and concentrated. To 
a solution of the crude product in THF (0.5 mL) was added aq. LiOH 
(3.2 mg, 0.075 mmol). After 3 h at r.t., the reaction mixture was 
filtered. The filtrate was purified by reverse phase HPLC [column: 
Phenomenex Luna (100 Å, 10 m, C18, 250 x 10 mm), solvents: a 
gradient elution of 85 : 15 to 100 : 0 MeOH : 0.05 M aqueous NH4HCO3 
over 30 min, flow rate: 3.0 mL/min, UV: 220nm] to afford 7 (7.5 
mg, 60% overall, retention time: 24.3 min). 1H NMR (400 MHz, 
Methanol-d4) δ 5.57 – 5.51 (m, 1H), 5.48 – 5.42 (m, 1H), 5.18 – 
5.06 (m, 11H), 4.55 – 4.48 (m, 2H), 4.41 – 4.10 (m, 6H), 4.03 – 
3.96 (m, 1H), 3.88 (q, J = 10.3 Hz, 2H), 3.74 (dd, J = 12.3, 5.1 
Hz, 1H), 3.53 (t, J = 9.5 Hz, 1H), 2.99 – 2.88 (m, 2H), 2.79 (s, 
1H), 2.31 (s, 3H), 2.14 – 2.03 (m, 31H), 1.99 (q, J = 7.8, 7.1 Hz, 
8H), 1.90 – 1.78 (m, 2H), 1.74 (s, 3H), 1.68 (s, 21H), 1.63 – 1.58 
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(m, 10H), 1.47 (d, J = 7.2 Hz, 3H), 1.41 (t, J = 6.7 Hz, 6H), 1.36 
(d, J = 7.2 Hz, 3H), 1.30 (d, J = 7.6 Hz, 8H), 0.89 (d, J = 8.1 
Hz, 2H); HRMS (EI) calcd for C86H144N7O21P2 ([M + H]+): 1672.9891, 
found: 1672.9908.
UDP-GlcN-C6-FITC (8): The title compound was synthesized 
according to the procedure reported previously: [20] 1H NMR (400 
MHz, Deuterium Oxide) δ 7.90 (d, J = 8.1 Hz, 1H), 7.71 – 7.63 (m, 
1H), 7.61 – 7.51 (m, 1H), 7.37 – 7.30 (m, 3H), 7.30 – 7.20 (m, 
4H), 5.99 – 5.85 (m, 2H), 5.52 (d, J = 6.3 Hz, 1H), 4.35 – 4.27 
(m, 3H), 4.26 – 4.13 (m, 2H), 4.12 – 4.00 (m, 2H), 3.92 – 3.84 (m, 
1H), 3.80 (dd, J = 16.2, 3.2 Hz, 1H), 3.76 – 3.69 (m, 2H), 3.62 – 
3.56 (m, 2H), 3.54 – 3.47 (m, 1H), 3.45 – 3.37 (m, 1H), 1.70 – 
1.57 (m, 4H), 1.46 – 1.33 (m, 4H); HRMS (ESI+) m/z calcd for 
C44H51N5NaO23P2S [M + H] 1134.2069, found: 1134.2084.
Kinetic studies: For the determination of apparent Km values, the 
substrates were added at various concentrations. Each reaction was 
applied the procedure described in Protocol A, but 2e-C55 was used 
instead of 1e. HyMraY was excluded. The apparent Km values were 
obtained by a nonlinear regression method using GraphPad Prism 
7.04. 
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The Supporting Information is available free of charge on the ACS 
Publications website at DOI: Insert ##.
Assay data, copies of NMR spectra, HPLC chromatogram of new 
compounds, and assay procedures. 
ABBREVIATIONS
GT; glycosyltransferase, MurG; UDP-N-acetylglucosamine:N-
acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-
acetylglucosamine transferase, Park’s nucleotide; UDP-MurNAc-
pentapeptide, Lipid I; MurNAc(pentapeptide)-pyrophosphoryl 
prenol, Lipid II; GlcNAc-MurNAc(pentapeptide)-pyrophosphoryl 
prenol GlcNAc; N-acetylglucosamine, GlcN; glucosamine, MurNAc; N-
acetylmuramic acid, UDP; uridine diphosphate, FITC; fluorescein 
isothiocyanate, UV-Vis; ultraviolet-visible, HPLC; high 
performance liquid chromatography, NADH; nicotinamide adenine 
dinucleotide phosphate, MurA; UDP-N-acetylglucosamine enolpyruvyl 
transferase, MurB; UDP-N-acetylenolpyruvoylglucosamine reductase, 
MurC; UDP-N-acetylmuramyl-L-alanine ligase, MurD; UDP-N-
acetylmuramoyl-L-alanine:D-glutamate ligase, MurE; UDP-N-
acetylmuramoyl-dipeptide-L-lysine ligase, MurF; UDP-N-
acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase, MraY/MurX; 
polyprenyl phosphate-GlcNAc-1-phosphate transferase, Hy; 
Hydrogenivirga sp., M. smeg; Mycobacterium smegmatis, HTS; high-
throughput screening, P-60; membrane fraction containing ~60 KDa 
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protein, Mtherm; Mycobacterium thermoresistibile, TB; 
tuberculosis, WecA; polyprenyl phosphate-GlcNAc-1-phosphate 
transferase, DPAGT1; dolichyl-phosphate GlcNAc-1-
phosphotransferase 1, tBu; tertiary-butyl, nBu; normal-butanol, 
DBU; 1,8-diazabicyclo[5.4.0]undec-7-ene, GOx; glyceroacetonide-
Oxyma, Su, N-hydroxysuccinimide, EDCI; 1-(3-dimethylaminopropyl)-
3-ethylcarbodiimide hydrochloride, Ac; acetyl, Bn; benzyl, Ph; 
phenyl, DMSO; dimethyl sulfoxide, OD; optical density, SAR; 
structure-activity relationship, Km; Michaelis constant, kcat; turnover 
number, Vmax; maximal velocity, Vero; kidney epithelial cells 
extracted from an African green monkey, PDB; Protein Data Bank.
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